4D Medicine Appoints Industry Veteran Tom Buckland as Chairman for 4Degra® Launch
4D Medicine Limited, a pioneer in resorbable biomaterials, has appointed industry veteran Tom Buckland as its new Chairman and Non-executive Director. The appointment comes as the company gears up to introduce its innovative product, 4Degra®, to global regulators and form strategic industry partnerships.
4Degra® is a versatile resorbable biomaterial designed for various implantable medical device applications. It has shown promising results in pre-clinical studies, demonstrating accelerated tissue healing and a lower foreign body response. The material's versatility extends to its formulations, with softer grades ideal for minimally invasive surgical devices and harder versions suited for more demanding uses.
Tom Buckland brings a wealth of experience to 4D Medicine Limited, having successfully led university medtech spin-outs like ApaTech Limited and Sirakoss to exits worth hundreds of millions. He has also held executive leadership roles within the medical device industry. Buckland is excited to join the company at this critical stage, believing 4Degra® to be a 'game-changer' in the bioresorbable medical device market.
The company has raised over £2.5 million in equity funding and established a production facility in Nottingham. This facility has the capacity to manufacture 1.5% of the global demand for medical-grade resorbable polymers. Philip Smith, CEO of 4D Medicine Limited, welcomes Buckland's appointment, highlighting his medical device experience and entrepreneurial flair.
With Tom Buckland at the helm and a promising product like 4Degra®, 4D Medicine Limited is well-positioned to make significant strides in the global medical device market. The company's strategic plans include introducing 4Degra® to global regulators and forming key industry partnerships.
